Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the Bigger quote. Means more than most other predictions.
Tend to disagree because a billion dollar drug prior to approval can trade at a $400 million market cap. Hence ~ 40 cents. They need to make the case for the platform and the other RAs. And to have real revenue projections. I hate to be negative but it is in management’s hands.
I think they meet it but what comes after. The PR should include more specifically what is happening with the other RAs and where they stand with Flaskworks.
Progress is what matters. Waiting around another 4 to 6 months for MHRA will be deadly to the shareholders.
Sorry Kab,
You and I have been invested in this stock for a very long time. They have a history of not meeting a schedule. It is poor execution. It is a fact. I want them to provide outlook and hit it. This 30 to 45 days is the first definitive schedule given since I can remember.
That is pretty funny. They stink at committing to time frames so you give them a buffer of 40% over.
We have been invested with them for so so long that you have to chuckle.
Some analysis group in Australia said late 2024 for approval in Australia. I do not know what they were basing that goal on.
I also stated this in my last response to you. You should read more closely.
“I do not have a back up transcript so I will take your word for it.”
Oct 13 is about 45 days.
I could care less where they filed first. But I remember more to the discussion and also more communication and awareness was promised for the company. The Big Biz Show doesn’t cut it with Wall Street.
I do not have a back up transcript so I will take your word for it. But the question is. Where are the other 3 RAs?
And strategic she did say. But also all 4 RAs during the last ASM.
The goal was this year. I recall just about everything she says.
That was interesting to read. I have no clue if they will even PR a submission and you may only find out with the next 10Q in November.
Also important to me is they stated last ASM they expected to file with all 4 RAs this year. So, if they do not let shareholders know where they are with the other 3 RAs when we finally get word with MHRA submission it would be a weak response in my opinion. I am sure others feel differently but that is my take. So if only MHRA submission from now until the end of the year is it. I would give them a grade of C-. They could rock our world with much more in the next 3 months and get the share price moving. Quarterly calls wouldn’t hurt at this point if they want to be transparent and act like a real company.
I only care about NWBO money and what comes to me. If you try and milk a stone they end up bankrupt and most harmed people end up with very little.
Extra plaintiffs only hurts my financial position. And yours be
Never much correlation because it is thinly traded there.
I bet if you had GBM, you would not hesitate. You would be on your knees pleading for insurance coverage of DC-Vax and asking why the government hasn’t moved yet.
I do not wish it on you but it would be a dark comedy.
Watching FOX business. Guest panelist said biotechs in this market is what to buy. Ones with new technology in tough to cure problems like cancer. He believes the rest of the market will not do too well.
Beating XBI by a wide margin over the last 1.5 months. More interest in this stock than most biotech companies recently.
The article is already under review. Doubt they are waiting for a single component approval for an article on combination trial data.
No. NWBO paid consultants (Cognate and UCLA) to figure out how to make it and the process is available to UCLA who works with it. Any changes to the process are owned by NWBO due to prior art patents.
It is the same ridiculous argument you guys put out daily. Even LL stating in a presentation or in writing that ALT-DC is DC-Vax cannot stop you folks from this FUD. Really willfully blind.
Really? There has been plenty of documented evidence posted by longs on this board for years. You should know better. It is like ignoring the facts that a father didn’t know what his son was doing on AF2 or talk about business with his partners.
Because we all know better. That is why. Get real.
So spoofing of this stock goes back over 5 years of data. Maybe we should forget it.
I bet when you have been wronged, you want your pound of flesh.
They also said they would apply to all the RAs this year at the ASM. Far cry from 6 months from now. Who knows?
Interesting post. I didn’t know about this meeting in a couple of weeks.
Valuing the company as a one indication (GBM) drug is their mistake. It is a platform for all cancer and other indications beyond. Almost limitless value.
It is the same mistake Cramer made with TSLA. He wanted to value it as a normal car company. There was that mentality on Walk Street with shorting TSLA. At $20 prior to splits Cramer told everyone to stay away. Big mistake.
All prior art in our patents apply to new discoveries and patents. Only strengthen claims for NWBO.
Nice try though.
Doc logic. This has zero logic. They traded well above $1 for quite a spell over the past 3 years. If above $1 was the criteria, they would have resisted during that long period.
At least he was honest about his trading. Others just crawl into oblivion. We have both been here a very long time and listened to the boasting of many traders knowing most of it not to be true. In the end we will both be in the win column. I expect ten times my money in one to two years. Be well.
Bucked the Biotech Index for the past month. Maybe word is starting to get out.
This article for peer review is probably why Al M. Had to take the data down from his website.
If they are not on major media outlets following peer review then shame on management. They could then talk about how the platform is intended for all cancer. It is done all the time with other one product companies. It would start getting us out of our hole and attract institutional interest with this visibility.
“Institutional investors purchased a net $249.0 thousand shares of NWBO during the quarter ended March 2019. This may signal that the smart money is gaining interest in this company as the 0.28% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Individual stakeholders 6.87%
Other institutional 0.27%
Mutual fund holders 0.01%”
As is stated. Smart money is starting to show some interest. As more and more catch on, the share price will only go up. Nice post.
“Also confirms in my opinion that the discussion over the combo trials either is at least close to final, or has at least making substantial progress. “
I agree with your take on that. Now as part of the SAB her knowledge with the vaccine can be used for other cancers. Not just neurosurgery. I think it is a good move for both Liau and the company.
Prior art follows when new patents are filed for changes. Bad argument for you.
No they cannot because NWBO paid for the development of DCVax. If NWBO agrees to run a trial on other cancers with the other companies then UCLA can make the vaccine for them to use in the trial. In short, the only commercial sales of the vaccine come from NWBO.
You know that is a lie. You have been effectively posting this kind of stuff over the years butt this company is about to reach critical mass. Not much time left for this sort of garbage.
It is only 1.7B authorized to be issued and the answer is yes.
“As this will involve her in time away from her job at UCLA I have little doubt that the money that NWBO will pay for her services will be paid not to her but paid directly to her employer, UCLA, in recompense. . “
I tend to disagree. NWBO already had access to her knowledge through the agreement with UCLA. This is a sea change for Liau. As a member of the SAB I would guess she could no longer be principal investigator in any upcoming trials or partake in them. Also the SAB members rewarded with millions of shares for success means she will be allowed to monetize her efforts for the past many years that UCLA prohibited her from holding stock in NWBO. It is an enormous change in her relationship and where it goes in the future with respect to NWBO is anyone’s guess.
I think he is implying you’re an idiot and he is a genius. I do not agree with his take. You, like many have based an investment decision on what the company stated their short term goals were over the past decade. Many of those goals were not followed through with actions and met.
I understand the stress and anger of any long term investor here. I find myself shifting assets to maintain my position in this company believing it will be ten times more in value from this price in six months to a year.
Be well.